交易中 07-07 11:30:08 美东时间
+2.475
+2.12%
今日重点评级关注:Chardan Capital:维持Ocular Therapeutix"买入"评级,目标价从21美元升至23美元;Guggenheim:维持Amylyx Pharmaceuticals"买入"评级,目标价从30美元升至40美元
06-26 17:42
Morgan Stanley analyst Adam Kramer maintains Camden Prop Trust (NYSE:CPT) with a Equal-Weight and raises the price target from $117 to $120.
06-26 01:41
Scotiabank analyst Nicholas Yulico maintains Camden Prop Trust (NYSE:CPT) with a Sector Underperform and raises the price target from $95 to $102.
06-18 21:59
Camden Property Trust (CPT) declares $1.06/share quarterly dividend, in line with previous. Forward yield 3.74% Payable July 17; for shareholders of record June 30; ex-div June 30. See CPT Dividend Sc...
06-16 04:50
今日重点评级关注:Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从6美元升至10美元;Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从14美元升至14.5美元
06-12 11:32
今日重点评级关注:Ascendiant Capital:维持NextTrip"买入"评级,目标价从7美元升至7.5美元;Maxim Group:维持Zevra Therapeutics"买入"评级,目标价从25美元升至35美元
06-11 09:55
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Ascendiant Capital cut the price target for Surgepays Inc (NASDAQ:SURG) from $5 to $3.5. Ascendiant Capital an...
06-10 20:24
Mizuho analyst Vikram Malhorta maintains Camden Prop Trust (NYSE:CPT) with a Outperform and raises the price target from $120 to $125.
06-10 20:07
今日重点评级关注:Ascendiant Capital:维持RenovoRx"买入"评级,目标价从13.5美元升至14美元;BTIG:维持Jade Biosciences"买入"评级,目标价从39美元升至74美元
06-02 16:25
Wells Fargo analyst James Feldman maintains Camden Prop Trust (NYSE:CPT) with a Equal-Weight and raises the price target from $106 to $107.
06-01 22:35